Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) – Pipeline Review, H2 2016’, provides in depth analysis on Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) targeted pipeline therapeutics.

The report provides comprehensive information on the Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13)

The report reviews Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) targeted therapeutics and enlists all their major and minor projects

The report assesses Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Rigontec GmbH

Spring Bank Pharmaceuticals, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC

3.6.4.13) Overview 7

Therapeutics Development 8

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC

3.6.4.13) - Products under Development by Stage of Development 8

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC

3.6.4.13) - Products under Development by Therapy Area 9

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC

3.6.4.13) - Products under Development by Indication 10

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC

3.6.4.13) - Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC

3.6.4.13) - Products under Development by Companies 13

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC

3.6.4.13) - Products under Development by Universities/Institutes 15

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC

3.6.4.13) - Therapeutics Assessment 17

Assessment by Monotherapy/Combination Products 17

Assessment by Mechanism of Action 18

Assessment by Route of Administration 19

Assessment by Molecule Type 20

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC

3.6.4.13) - Companies Involved in Therapeutics Development 22

Rigontec GmbH 22

Spring Bank Pharmaceuticals, Inc. 23

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC

3.6.4.13) - Drug Profiles 24

ImOl-100 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

Oligonucleotide to Activate RIG-1 for Influenza and Viral Infections - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

SB-44 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

SB-9200 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

SB-9400 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

SB-9941 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

SB-9946 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC

3.6.4.13) - Dormant Projects 35

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC

3.6.4.13) - Featured News & Press Releases 36

Jun 22, 2016: Spring Bank Pharmaceuticals Doses the First Patient in the ACHIEVE Global Phase 2 Program of SB 9200 in Hepatitis B 36

Apr 21, 2016: Spring Bank Pharmaceuticals Presents Data on Immunomodulatory Agent SB 9200 at the 29th International Conference on Antiviral Research 37

Apr 14, 2016: Spring Bank Pharmaceuticals Presents Data on Immunomodulatory Agent SB 9200 at the 2016 European Association for the Study of the Liver Annual Meeting 39

Mar 31, 2016: Spring Bank Pharmaceuticals to Present Results from Preclinical Studies of SB 9200 in HBV and HCV at EASL 2016 40

Feb 23, 2016: Spring Bank Pharmaceuticals Announces Grant of European Patent for SMNH Analogs Including SB 9200 41

Dec 08, 2015: Spring Bank Pharmaceuticals Reports Preclinical Data on the Use of SB 9200 with Entecavir in the Woodchuck Model of HBV 41

Nov 16, 2015: Spring Bank Pharmaceuticals Presents Positive Phase 1 Data on SB 9200 at the 2015 American Association for the Study of Liver Diseases Annual Meeting 42

Oct 13, 2015: Spring Bank Pharmaceuticals Announces Presentation of Results from Phase I Clinical Trial Supporting the Novel Mechanism of Action of SB 9200 in Patients with Hepatitis C at The Liver Meeting 43

Apr 27, 2015: Spring Bank Pharmaceuticals Presents Preclinical and Clinical Data on Immunomodulatory Agent SB 9200 at the 2015 Annual Meeting of the European Association for the Study of the Liver 43

Apr 13, 2015: Spring Bank Pharmaceuticals to Present HBV and HCV Results with SB 9200 at EASL 2015 45

Mar 12, 2015: Spring Bank Pharmaceuticals to Present Novel Approach to Hepatitis B Treatment at the 2015 AASLD and Industry Colloquium 46

Sep 18, 2014: Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens 47

Jun 23, 2014: Spring Bank Pharmaceuticals Presents at the Nucleic Acid Summit 2014 48

May 12, 2014: Spring Bank Pharmaceuticals Announces Oral and Poster Presentations At The 27th International Conference On Antiviral Research 48

Nov 26, 2013: Spring Bank Pharmaceuticals Commences Multiple Ascending Dose (MAD) Stage of Phase 1 clinical in HCV Patients 49

Appendix 50

Methodology 50

Coverage 50

Secondary Research 50

Primary Research 50

Expert Panel Validation 50

Contact Us 50

Disclaimer 51

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Products under Development by Companies, H2 2016 14

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Products under Investigation by Universities/Institutes, H2 2016 16

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Stage and Mechanism of Action, H2 2016 18

Number of Products by Stage and Route of Administration, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 21

Pipeline by Rigontec GmbH, H2 2016 22

Pipeline by Spring Bank Pharmaceuticals, Inc., H2 2016 23

Dormant Projects, H2 2016 35

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Stage and Mechanism of Action, H2 2016 18

Number of Products by Stage and Routes of Administration, H2 2016 19

Number of Products by Molecule Types, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 20

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports